Drugs/Approval·openFDA

Aspercreme with Lidocaine No-Mess Applicator — Chattem, Inc. drug label update

LowPublished May 29, 2026· AI-analyzed May 29, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Chattem, Inc. has issued an update for the drug label of Aspercreme with Lidocaine No-Mess Applicator, indicated for the temporary relief of pain.

Who it affects

This update affects Chattem, Inc., as well as regulatory and quality personnel responsible for the compliance and labeling of topical over-the-counter analgesic products.

Why it matters

Label updates for established OTC products typically reflect changes in safety information, usage directions, or manufacturing details. While the source does not specify the exact nature of the text change, such updates require strict version control and alignment between regulatory filings and commercial distribution to maintain compliance with FDA drug listing requirements.

Practical takeaway

Regulatory teams should review the updated labeling for Aspercreme with Lidocaine to ensure internal documentation and physical packaging reflect the most recent FDA-submitted version. QA should verify that any changes in the applicator or formulation documentation align with the updated label claims for temporary pain relief.

FDA source material

Aspercreme with Lidocaine No-Mess Applicator (Chattem, Inc.). Use for the temporary relief of pain

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.